135 related articles for article (PubMed ID: 11465809)
41. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study.
Stathopoulos GP; Boulikas T; Vougiouka M; Deliconstantinos G; Rigatos S; Darli E; Viliotou V; Stathopoulos JG
Oncol Rep; 2005 Apr; 13(4):589-95. PubMed ID: 15756428
[TBL] [Abstract][Full Text] [Related]
42. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin.
Veal GJ; Griffin MJ; Price E; Parry A; Dick GS; Little MA; Yule SM; Morland B; Estlin EJ; Hale JP; Pearson AD; Welbank H; Boddy AV
Br J Cancer; 2001 Apr; 84(8):1029-35. PubMed ID: 11308249
[TBL] [Abstract][Full Text] [Related]
43. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer.
Hansen RM; Ryan L; Anderson T; Krzywda B; Quebbeman E; Benson A; Haller DG; Tormey DC
J Natl Cancer Inst; 1996 May; 88(10):668-74. PubMed ID: 8627643
[TBL] [Abstract][Full Text] [Related]
44. Beneficial effect of acetylcysteine on cisplatin nephrotoxicity in rats.
Appenroth D; Winnefeld K; Schröter H; Rost M
J Appl Toxicol; 1993; 13(3):189-92. PubMed ID: 8326088
[TBL] [Abstract][Full Text] [Related]
45. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
46. Enhancement of methotrexate nephrotoxicity after cisplatin therapy.
Goren MP; Wright RK; Horowitz ME; Meyer WH
Cancer; 1986 Dec; 58(12):2617-21. PubMed ID: 2877729
[TBL] [Abstract][Full Text] [Related]
47. Cisplatin nephrotoxicity: experimental and clinical studies.
Daugaard G
Dan Med Bull; 1990 Feb; 37(1):1-12. PubMed ID: 2178884
[TBL] [Abstract][Full Text] [Related]
48. Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats.
Hanada K; Odaka K; Kudo A; Ogata H
Pharm Res; 1999 Oct; 16(10):1589-95. PubMed ID: 10554102
[TBL] [Abstract][Full Text] [Related]
49. Dose-related nephrotoxicity of carboplatin in children.
English MW; Skinner R; Pearson AD; Price L; Wyllie R; Craft AW
Br J Cancer; 1999 Sep; 81(2):336-41. PubMed ID: 10496362
[TBL] [Abstract][Full Text] [Related]
50. [Pharmacokinetic properties of platinium derivatives].
Boisdron-Celle M; Lebouil A; Allain P; Gamelin E
Bull Cancer; 2001 Aug; 88 Spec No():S14-9. PubMed ID: 11567909
[TBL] [Abstract][Full Text] [Related]
51. Kinetics of plasma platinum in a hemodialysis patient receiving repeated doses of cisplatin.
Hirai K; Ishiko O; Sumi T; Kanaoka Y; Ogita S
Oncol Rep; 2000; 7(6):1243-5. PubMed ID: 11032923
[TBL] [Abstract][Full Text] [Related]
52. Risk factors for cisplatin-induced long-term nephrotoxicity in pediatric cancer survivors.
Arga M; Oguz A; Pinarli FG; Karadeniz C; Citak EC; Emeksiz HC; Duran EA; Soylemezoglu O
Pediatr Int; 2015 Jun; 57(3):406-13. PubMed ID: 25441241
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration.
Desoize B; Berthiot G; Manot L; Coninx P; Dumont P
Eur J Cancer; 1996 Sep; 32A(10):1734-8. PubMed ID: 8983282
[TBL] [Abstract][Full Text] [Related]
54. The evaluation of cisplatin effect on tubular function in children on chemotherapy.
Zareifar S; Jafari H; Geramizadeh B; Basiratnia M; Golafshan H; Cohan N; Mehravar Z; Hamidi R
Pediatr Hematol Oncol; 2013 Feb; 30(1):18-24. PubMed ID: 23163346
[TBL] [Abstract][Full Text] [Related]
55. Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Ahn JH; Kang YK; Kim TW; Bahng H; Chang HM; Kang WC; Kim WK; Lee JS; Park JS
Cancer Chemother Pharmacol; 2002 Aug; 50(2):104-10. PubMed ID: 12172973
[TBL] [Abstract][Full Text] [Related]
56. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.
Nagai N; Hotta K; Yamamura H; Ogata H
Cancer Chemother Pharmacol; 1995; 36(5):404-10. PubMed ID: 7634382
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration.
Ikeda K; Terashima M; Kawamura H; Takiyama I; Koeda K; Takagane A; Sato N; Ishida K; Iwaya T; Maesawa C; Yoshinari H; Saito K
Jpn J Clin Oncol; 1998 Mar; 28(3):168-75. PubMed ID: 9614438
[TBL] [Abstract][Full Text] [Related]
58. Renal impairment and hypertension in brain tumor patients treated in childhood are mainly associated with cisplatin treatment.
Pietilä S; Ala-Houhala M; Lenko HL; Harmoinen AP; Turjanmaa V; Mäkipernaa A
Pediatr Blood Cancer; 2005 Apr; 44(4):363-9. PubMed ID: 15586356
[TBL] [Abstract][Full Text] [Related]
59. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity.
Reece PA; Stafford I; Russell J; Khan M; Gill PG
J Clin Oncol; 1987 Feb; 5(2):304-9. PubMed ID: 3806171
[TBL] [Abstract][Full Text] [Related]
60. Low urine osmolarity as a determinant of cisplatin-induced nephrotoxicity.
Polycarpe E; Arnould L; Schmitt E; Duvillard L; Ferrant E; Isambert N; Duvillard C; Beltramo JL; Chevet D; Chauffert B
Int J Cancer; 2004 Aug; 111(1):131-7. PubMed ID: 15185354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
